Trial Profile
A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Nov 2018
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2018 Status changed to discontinued.
- 07 Nov 2018 Status changed to discontinued.
- 19 May 2015 Planned primary completion date changed from 1 Sep 2016 to 1 May 2015 as per ClinicalTrials.gov record.